FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

Autor:	Mark Dixon, Maneesh Tandon, C. Utoft Niemann, Liliya Sivcheva, Karl-Anton Kreuzer, Kathryn Humphrey, Laura M. Fogliatto, Simon Warburton, Sue Robinson, Anthonie Willem Langerak, C M Wendtner, Eugen Tausch, Barbara Eichhorst, Anna Marina Liberati, Robert Weinkove, Sandra Robrecht, Stephan Stilgenbauer, Kirsten Fischer, Javier Pinilla-Ibarz, Mehrdad Mobasher, M. Porro Lurà, Matthias Ritgen, Valentin Goede, Thomas J. Kipps, William Schary, Sebastian Boettcher, Michael Hallek, K. Le Dû, Stephen Opat, Othman Al-Sawaf, A. M. Fink, Jasmin Bahlo, Olga Samoylova
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Venetoclax Hematology General Medicine Minimal Residual Disease Negativity chemistry.chemical_compound Fixed duration chemistry Obinutuzumab Internal medicine medicine In patient business
Zdroj:	Hematological Oncology. 37:82-84
ISSN:	0278-0232
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c6058960fee67ca2d46c10b3b69c4a09 https://doi.org/10.1002/hon.52_2629 Zobrazit plný text záznamu Plný text